Foresight Diagnostics utilizes PhasED-Seq™ technology to detect circulating tumor DNA (ctDNA) from a simple blood draw, enabling the identification of minimal residual disease (MRD) across various cancer types. This ultra-sensitive platform provides actionable insights throughout the patient treatment journey, enhancing cancer drug development and patient care.
Funding
$86.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting minimal residual disease (MRD) in cancer patients lack the sensitivity needed to identify recurrence early, especially when circulating tumor DNA (ctDNA) levels are very low after treatment. This limitation can lead to delayed interventions and potentially poorer patient outcomes.
Solution
Foresight Diagnostics offers Foresight CLARITY™, an ultra-sensitive MRD platform that uses PhasED-Seq™ technology to detect ctDNA from a simple blood draw. By identifying and tracking patient- and tumor-specific phased variants (PVs), the platform achieves a detection limit of less than one part per million, significantly improving upon traditional methods. This enhanced sensitivity allows for the identification of residual disease at key points in the treatment journey, providing clinicians with actionable data to inform treatment decisions. The increased accuracy and performance of Foresight CLARITY™ ensures greater confidence in research and clinical development programs, strengthening hazard ratios and better delineating the effect of treatment.
Target Audience
The primary audience includes biopharmaceutical companies and academic researchers focused on oncology drug development and clinical research, as well as clinicians seeking to improve patient care through more accurate MRD detection.
Features
- Utilizes PhasED-Seq™ technology to track phased variants (PVs), enhancing ctDNA detection accuracy.
- Achieves detection limits below one part per million, up to 100 times more sensitive than first-generation liquid biopsy methods.
- Reduces background noise in sequencing data, decreasing false negative and false positive rates.
- Facilitates the use of MRD as an enrollment biomarker and accelerates clinical trials with MRD as an endpoint.
- Assay is performed in a CLIA-certified and ISO 27001-2013 certified laboratory.